Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Guitty Eghbali-Fatourechi, … , David L. Lacey, B. Lawrence Riggs
Guitty Eghbali-Fatourechi, … , David L. Lacey, B. Lawrence Riggs
Published April 15, 2003
Citation Information: J Clin Invest. 2003;111(8):1221-1230. https://doi.org/10.1172/JCI17215.
View: Text | PDF
Article Aging

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

  • Text
  • PDF
Abstract

Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab’s against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17β-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.

Authors

Guitty Eghbali-Fatourechi, Sundeep Khosla, Arunik Sanyal, William J. Boyle, David L. Lacey, B. Lawrence Riggs

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Representative flow cytometry dot plots sorted for BAP+/RANKL+ cells fro...
Representative flow cytometry dot plots sorted for BAP+/RANKL+ cells from bone marrow aspirates of an untreated postmenopausal woman. (a) Forward/side light scatter profile of unstained cells following Ficoll-Paque density centrifugation. The R1 gate represents the mononuclear cells that include the MSCs. The R2 gate represents granulocyte precursor cells and these are excluded from analysis. (b) The dot plot profile of the autofluorescence from the irrelevant mouse IgG1 isotype that was used as a control for anti-BAP Ab. (c) The dot plot profile of the BAP+ cells (left upper quadrants in a–f) as assessed by single-color flow cytometry using the monoclonal anti-BAP (B4-78) stained with a PE-conjugated secondary Ab. The quadrant limits were set so that the left upper quadrant that defines the specific fluorescence for the BAP+ cells contains less than 5% of the nonspecific fluorescence from the irrelevant mouse IgG1 isotype control. (d and e) The analogous single-color flow cytometry using the human Fc-FITC control and OPG-Fc-FITC probe for RANKL+ sorted cells, respectively. (f) The dual-color dot plot profile for BAP+/RANKL– sorted cells (left upper quadrant), BAP–/RANKL+ sorted cells (right lower quadrant), and for combined BAP+ and RANKL+ sorted cells (right upper quadrant). The numerical percentages represent the stained cells per quadrant expressed as a proportion of total mononuclear cells in the R1 gate.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts